Aquestive Therapeutics (AQST) Share-based Compensation (2018 - 2026)

Aquestive Therapeutics' Share-based Compensation history runs 9 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 46.06% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $8.4 million (up 17.58% YoY), while the FY2025 annual figure was $7.6 million, up 7.4% from the prior year.
• Share-based Compensation was $2.3 million for Q1 2026 at Aquestive Therapeutics, up from $1.4 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $2.8 million in Q3 2025 to a low of $344000.0 in Q1 2023.
• Historically, Share-based Compensation has averaged $1.4 million across 5 years, with a median of $1.5 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Share-based Compensation sank 71.84% in 2022, then surged 359.3% in 2024.
• A 5-year view of Share-based Compensation shows it stood at $714000.0 in 2022, then soared by 31.65% to $940000.0 in 2023, then soared by 155.64% to $2.4 million in 2024, then sank by 42.74% to $1.4 million in 2025, then surged by 68.46% to $2.3 million in 2026.
• The last three Share-based Compensation figures came in at $2.3 million (Q1 2026), $1.4 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.